Investing.com - Fresh Tracks Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Fresh Tracks Therapeutics announced earnings per share of $-2.0700 on revenue of $486K. Analysts polled by Investing.com anticipated EPS of $-1.4300 on revenue of $206.67K.
Fresh Tracks Therapeutics shares are down 28.35% from the beginning of the year, still down 90.66% from its 52 week high of $18.94 set on April 19.
Fresh Tracks Therapeutics follows other major Healthcare sector earnings this month
Fresh Tracks Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar